Last reviewed · How we verify
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
The objective of this study is to evaluate the bioequivalence of a tablet formulation versus a capsule formulation of ASP8273 following a single dose under fasted condition in subjects with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study will also evaluate the safety and tolerability of a tablet formulation as a single dose and a capsule formulation as a single and multiple dose of ASP8273 in subjects with NSCLC harboring EGFR mutations.
Details
| Lead sponsor | Astellas Pharma Global Development, Inc. |
|---|---|
| Phase | PHASE1 |
| Status | TERMINATED |
| Enrolment | 3 |
| Start date | Fri Mar 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jun 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Epidermal Growth Factor Receptor (EGFR) Mutations
Interventions
- naquotinib
Countries
United States